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Abstract
Various risk models with differing discriminatory power and predictive accuracy 
have been used to predict right ventricular failure (RVF) after left ventricular assist 
device (LVAD) placement. There remains an unmet need for a contemporary risk 
score for continuous flow (CF)‐LVADs. We sought to independently validate and 
compare existing risk models in a large cohort of patients and develop a simple, yet 
highly predictive risk score for acute, severe RVF. Data from the Mechanical 
Circulatory Support Research Network (MCSRN) registry, consisting of patients 
who underwent CF‐LVAD implantation, were randomly divided into equal‐sized 
derivation and validation samples. RVF scores were calculated for the entire sample, 
and the need for a right ventricular assist device (RVAD) was the primary endpoint. 
Candidate predictors from the derivation sample were subjected to backward step-
wise logistic regression until the model with lowest Akaike information criterion 
value was identified. A risk score was developed based on the identified variables 
and their respective regression coefficients. Between May 2004 and September 2014, 
734 patients underwent implantation of CF‐LVADs [HeartMate II LVAD, 76% 
(n = 560), HeartWare HVAD, 24% (n = 174)]. A RVAD was required in 4.5% 
(n = 33) of the patients [Derivation cohort, n = 15 (4.3%); Validation cohort, n = 18 
(5.2%); P = 0.68)]. 19.5% of the patients (n = 143) were female, median age at im-
plant was 59 years (IQR, 49.4–65.3), and median INTERMACS profile was 3 (IQR, 
2–3). RVAD was required in 4.5% (n = 33) of the patients. Correlates of acute, se-
vere RVF in the final model included heart rate, albumin, BUN, WBC, cardiac index, 
and TR severity. Areas under the curves (AUC) for most commonly used risk predic-
tors ranged from 0.61 to 0.78. The AUC for the new model was 0.89 in the derivation 
and 0.92 in the validation cohort. Proposed risk model provides very high discrimi-
natory power predicting acute severe right ventricular failure and can be reliably 
applied to patients undergoing placement of contemporary continuous flow left ven-
tricular assist devices.
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1 |  INTRODUCTION
Development of right ventricular failure (RVF) after con-
tinuous‐flow left ventricular assist device (CF‐LVAD) im-
plantation remains a leading cause of perioperative morbidity, 
end‐organ dysfunction, and mortality.1‒3 Consequently, sev-
eral risk scores and indices have been reported as useful 
predictors for the development of RVF following LVAD im-
plantation.1,4‒10 Most have been developed based on the ex-
perience of single institutions and small numbers of patients 
(Table 1). With improved predictive capabilities, patients at 
high risk for RVF can be preidentified in the preoperative 
period and a strategy of short‐term support with a temporary 
right ventricular assist device (RVAD) has been shown to re-
duce perioperative morbidity, mortality, and reduce hospital 
length of stay.11
However, many risk scores were derived from popula-
tions treated with pulsatile LVADs that are no longer used in 
clinical practice and the outcome of RVF is variably defined. 
There is currently no RVF risk score that is uniformly ac-
cepted. As such, there is a need for developing and validating 
a contemporary risk score in a large multicenter patient co-
hort that focuses on current‐generation CF‐LVADs.
2 |  METHODS
A collaborative multi‐institutional retrospective analysis of 
all primary CF‐LVAD implanted as part of the Mechanical 
Circulatory Support Research Network (MCSRN) database 
was conducted. MCSRN is a prospectively collected retro-
spective database run by a dedicated long‐term data man-
ager using REDCap platform, who coordinated data entry at 
each member site. At the time of this project’s performance, 
MCRN consisted of data from Mayo Clinic, University of 
Michigan, and Vanderbilt University. Acute severe RV fail-
ure was defined as need for RVAD support within the index 
CF‐LVAD hospital stay. RVAD support included all tem-
porary and durable right‐sided devices. Data used as input 
variables were acquired from patients’ preoperative workup, 
including preoperative laboratory workup, echocardiograms, 
and cardiac catheterization.
The MCSRN data set was divided randomly into 2 equal 
samples (n = 367 each). The derivation cohort was used for 
MCSRN RVF risk model development, while a validation co-
hort was used for its validation. The MCSRN RVF risk score 
was developed using preimplant data from the derivation co-
hort. With the goal to maximally utilize the continuous data, 
dichotomization into categorical variables was avoided when 
developing the new risk model. Instead, logarithmic data 
transformation was utilized as needed for continuous data 
with skewed distribution and highly variable absolute ranges.
Candidate variables for the MCSRN RVF risk score in-
cluded preoperative patient characteristics and demograph-
ics (age, gender, race, height, body mass index, body surface 
area, heart failure etiology, device indication), comorbidities 
(atrial fibrillation, hypertension, diabetes, dialysis‐depen-
dent renal failure), preoperative clinical status (intubated, 
intraaortic balloon pump, INTERMACS profile), preoper-
ative laboratory (serum creatinine level, serum total biliru-
bin, aspartate aminotransferase, alanine aminotransferase, 
albumin, brain natriuretic peptide, hemoglobin, white blood 
cell count, platelet count, international normalized ratio), car-
diopulmonary hemodynamics (preoperative heart rate, mean 
arterial pressure, central venous pressure, systolic pulmonary 
artery pressure, pulmonary capillary wedge pressure, cardiac 
index), and echocardiographic (left ventricular ejection frac-
tion, left ventricular end diastolic diameter, mitral regurgi-
tation grade, tricuspid regurgitation grade, right ventricular 
dysfunction severity) variables (For regurgitation severity, 
0 = none, 0.5 = trace, 1 = mild, 1.5 = mild to moderate, 
2 = moderate, 2.5 = moderate to severe, 3 = severe).
The MSCRN RVF Risk Score was compared to com-
monly used RVF predictor scores and indices, including the 
ones not reported in the literature for this purpose [central 
venous pressure to pulmonary capillary wedge pressure ratio 
(CVP/PCWP), model for end‐stage liver disease (MELD)]. A 
nested cohort was used to allow comparative analyses of the 
predictor models.
2.1 | Statistical analyses
R statistical software, version 3.2.3 (R Foundation for 
Statistical Computing, Vienna, Austria) was used for data 
analysis and visualization. For continuous variables, me-
dian with interquartile range (IQR) was used given signifi-
cant deviation from normality (P < 0.05, Shapiro‐Wilk test). 
Categorical data were presented as percentages and analyzed 
using the chi‐square test. Numeric values of the severity of 
valve regurgitation were treated as ranks on the ordinal scale. 
Continuous variables were compared using Wilcoxon rank‐
sum test, while categorical variables were analyzed using the 
chi‐square test.
Candidate predictors for the MCSRN RVF risk model 
were entered into the model development process and sub-
jected to backward stepwise logistic regression based on 
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T A B L E  2  Baseline patient characteristics
Variable Derivation (n = 367) Validation (n = 367) Total (n = 734) P‐value
Patient demographics and comorbidities
Age, median [IQR] 58.5 [48.1, 65.0] 60.0 [50.2, 65.8] 59.1 [49.4, 65.3] 0.05
Female (%) 80 (21.8) 63 (17.2) 143 (19.5) 0.14
BMI, median [IQR] 28.5 [24.6, 33.0] 28.0 [24.0, 32.0] 28.3 [24.3, 32.6] 0.22
BSA, median [IQR] 2.0 [1.9, 2.2] 2.0 [1.9, 2.2] 2.0 [1.9, 2.2] 0.46
Ischemic etiology (%) 174 (47.5) 186 (51.4) 360 (49.5) 0.34
Bridge to transplant (%) 211 (57.5) 225 (61.5) 436 (59.5)
Atrial fibrillation (%) 141 (38.4) 128 (35.0) 269 (36.7) 0.37
HTN (%) 178 (48.5) 186 (50.8) 364 (49.7) 0.58
Diabetes (%) 106 (29.4) 146 (40.1) 252 (34.8) 0.00
Dialysis (%) 8 (2.2) 5 (1.4) 13 (1.8) 0.58
Preoperative variables
Intubated preoperatively (%) 8 (3.8) 10 (4.9) 18 (4.4) 0.75
Preoperative inotropic support (%) 269 (73.7) 285 (78.1) 554 (75.9) 0.19
Preoperative vasopressors (%) 80 (38.1) 73 (36.0) 153 (37.0) 0.73
Preoperative IABP (%) 165 (45.6) 163 (44.9) 328 (45.2) 0.91
Temporary cardiac support bridge (%) 27 (11.2) 23 (8.8) 50 (10.0) 0.46
INTERMACS profile, median [IQR] 3.0 [2.0, 3.5] 3.0 [2.0, 3.0] 3.0 [2.0, 3.0] 0.76
Device type
HeartMate II LVAD (%) 282 (76.8) 278 (75.7) 560 (76.3)
HeartWare HVAD (%) 85 (23.2) 89 (24.3) 174 (23.7) 0.79
Reoperative sternotomy (%) 115 (31.3) 123 (33.7) 238 (32.5) 0.55
Preoperative laboratory variables
BUN, median [IQR] 25.0 [19.0, 36.0] 27.0 [19.0, 39.0] 26.0 [19.0, 37.0] 0.16
Creatinine, median [IQR] 1.3 [1.0, 1.6] 1.3 [1.1, 1.6] 1.3 [1.1, 1.6] 0.30
eGFR, median [IQR] 54.0 [41.0, 60.0] 53.0 [41.6, 60.0] 54.0 [41.0, 60.0] 0.73
AST, median [IQR] 31.0 [24.0, 49.0] 31.0 [25.0, 46.0] 31.0 [24.0, 47.0] 0.75
ALT, median [IQR] 29.0 [19.0, 50.0] 30.0 [20.0, 47.5] 30.0 [20.0, 49.0] 1.00
Total bilirubin, median [IQR] 1.0 [0.7, 1.6] 1.0 [0.7, 1.5] 1.0 [0.7, 1.5] 0.32
Albumin, median [IQR] 3.7 [3.4, 4.1] 3.8 [3.3, 4.0] 3.7 [3.4, 4.0] 0.64
BNP, median [IQR] 764.0 [373.8, 1310.8] 652.0 [289.5, 1196.2] 698.0 [325.5, 1284.5] 0.08
WBC, median [IQR] 7.9 [6.1, 9.9] 7.8 [6.3, 9.6] 7.9 [6.2, 9.8] 0.85
INR, median [IQR] 1.2 [1.1, 1.4] 1.2 [1.1, 1.4] 1.2 [1.1, 1.4] 0.54
Preoperative hemodynamics
Heart rate, median [IQR] 80.0 [70.0, 95.0] 80.0 [71.0, 93.5] 80.0 [70.0, 94.2] 0.55
Systolic PA pressure, median [IQR] 47.0 [39.0, 58.0] 46.0 [38.0, 58.0] 47.0 [38.0, 58.0] 0.71
Diastolic PA pressure, median [IQR] 23.0 [16.0, 29.0] 23.0 [18.0, 28.0] 23.0 [18.0, 28.0] 0.86
Median PA pressure, median [IQR] 33.0 [27.0, 41.0] 33.0 [28.0, 39.0] 33.0 [27.0, 40.0] 0.69
PCWP, median [IQR] 22.0 [15.2, 26.0] 22.0 [16.0, 26.0] 22.0 [16.0, 26.0] 0.60
Cardiac output, median [IQR] 4.4 [3.5, 5.2] 4.1 [3.4, 5.0] 4.3 [3.4, 5.2] 0.02
Cardiac index, median [IQR] 2.1 [1.8, 2.5] 2.1 [1.7, 2.5] 2.1 [1.7, 2.5] 0.06
RVSWI, median [IQR] 508.0 [367.8, 715.5] 492.0 [326.0, 660.0] 504.0 [341.7, 690.0] 0.12
Echocardiographic parameters
LVEF, median [IQR] 15.0 [10.0, 20.0] 15.0 [11.0, 20.0] 15.0 [10.0, 20.0] 0.95
RVEDD, median [IQR] 3.2 [2.9, 3.9] 3.4 [3.0, 3.7] 3.4 [3.0, 3.7] 0.61
(Continues)
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Akaike Information Criterion (AIC).12 First, highly cor-
related data in the same category (eg, systolic, diastolic, and 
mean PA pressure values) were subjected to regression based 
on the lowest AIC value to eliminate all but most promising 
variables prior to entering them into the model develop-
ment process. Baseline variables were then entered into the 
backward stepwise logistic regression process. The baseline 
variables entered into the analysis are provided in Table 2. 
Each time, 8–12 variables were entered into the stepwise 
regression process to avoid overfitting the model. The low-
est AIC level was used to identify the best fitting model. 
Calibration of the model was assessed using the Hosmer‐
Lemeshow goodness of fit test. Odds of RVF development 
were assessed in a continuous manner using restricted cubic 
splines analysis.
Based on the variables in the final model and their respec-
tive regression coefficients developed from the derivation 
cohort, a novel risk score termed the MCSRN RVF risk score 
was developed. The risk score was tested on the validation 
cohort to assess its validity and calibration.
Receiver operating characteristic (ROC) analysis was 
used to derive areas under the curve (AUC) for assessing 
the discriminatory power of the risk models (including the 
MCSRN RVF risk model), and to identify the optimal cut‐
off level between sensitivity and specificity of the novel risk 
score. DeLong’s test13 was used for statistical comparison of 
ROC curves.
For all analysis (except where mentioned), a P < 0.05 was 
considered statistically significant. Local IRB approval was 
granted for data analysis as part of the MCSRN.
3 |  RESULTS
Between May 2004 and September 2014, 734 patients under-
went implantation of CF‐LVADs [HeartMate II LVAD, 76% 
(n = 560), HeartWare HVAD, 24% (n = 174)]. 19.5% of the 
patients (n = 143) were female, median age at implant was 
59 years (IQR, 49.4–65.3), and median INTERMACS pro-
file was 3 (IQR, 2–3). RVAD was required in 4.5% (n = 33) 
of the patients [Derivation sample, n = 15 (4.3%); validation 
sample, n = 18 (5.2%); P = 0.68]. Patient demographics and 
baseline clinical characteristics for each group as well as the 
entire sample are shown in Table 2.
3.1 | Derivation of the MCSRN RVF 
risk score
The candidate variables were entered into the multivariable 
regression. The following variables were identified as corre-
lates of RVF in the derivation cohort: heart rate, WBC count, 
albumin level, BUN level, cardiac index, and the numeric 
value of the severity of the tricuspid valve’s regurgitation 
(Table 3). Using regression coefficients in the final model 
as respective weights of these variables, the following for-
mula was created to provide the numeric risk score (please 
refer to the online supplement for the Excel‐based risk score 
calculator):
The numeric values of the MCSRN RVF risk model 
ranged from 14.5 to 26.9 and were normally distributed 
(P = 0.2, Shapiro‐Wilk test) with mean value of 20.2 ± 1.8. 
The area under the curve was 0.86 (95% CI 0.74–0.99) for 
the derivation cohort and 0.92 (95% CI 0.85–0.99) for the 
validation cohort indicating very good discriminatory power. 
The area under the curve for the entire sample was 0.89 (95% 
CI 0.82–0.96) (Figure 1). Continuous analysis showed ex-
ponential increase of odds ratio of requiring an RVAD with 
increasing risk score numbers (P < 0.001) (Figure 2). The 
Hosmer‐Lemeshow test was consistent with good calibration 
(derivation sample, P = 0.45; validation sample, P = 0.57, 
entire sample, P = 0.17).
4.2944 × log (HR) − 4.4917 × log (Albumin)
+ 1.2029 × log (BUN) + 1.0599 × log (WBC)
− 1.0364 × log (CI) + 0.8213 × numeric TR severity
Variable Derivation (n = 367) Validation (n = 367) Total (n = 734) P‐value
LVEDD, median [IQR] 66.0 [46.5, 75.5] 66.0 [8.9, 75.0] 66.0 [39.0, 75.0] 0.35
LVESD, median [IQR] 59.0 [8.9, 69.0] 58.0 [7.8, 67.0] 59.0 [8.1, 68.0] 0.32
Median degree of MR [IQR] 2.0 [1.0, 4.0] 2.0 [2.0, 4.0] 2.0 [1.0, 4.0] 0.24
Median degree of TR [IQR] 2.0 [1.0, 3.0] 2.0 [1.0, 3.0] 2.0 [1.0, 3.0] 0.29
Median degree of RV dysfunction [IQR] 2.0 [2.0, 3.0] 2.0 [2.0, 3.0] 2.0 [2.0, 3.0] 0.80
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; BNP, brain natriuretic peptide; BUN, blood urea ni-
trogen; eGFR, estimated glomerular filtration rate; HTN, hypertension; IABP, intra‐aortic balloon pump; INR, international normalized ratio; LVEDD, left ventricular 
end diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic dimension; MR, mitral regurgitation; PCWP, pulmonary capillary 
wedge pressure; RVEDD, right ventricular end diastolic dimension; RVSWI, right ventricular stroke work index; TR, tricuspid regurgitation; WBC, white blood cell 
count.
T A B L E  2  (Continued)
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Based on the ROC analysis of the entire patient sample, 
the cut‐off level of 21.9 yielded the optimal balance between 
sensitivity (88.4%) and specificity (78.3%). The resulting 
positive predictive value was 98.8%, and the negative pre-
dictive value was 25.7%. For clinical simplicity, patients can 
be stratified into a low‐, intermediate‐, and high‐risk groups 
using the thresholds 20 and 22, where the incidence of an 
RVAD was 78% above the cut‐off of 22, it was 4% below the 
cut‐off of 20.
3.2 | Comparison of RVF risk scores
Areas under the curves for most commonly used RVF 
risk predictors as calculated by us ranged from poor (AUC 
0.60–0.69) to satisfactory (AUC 0.70–0.79): pulmonary 
artery pulsatility index (PAPI) (AUC 0.78), central ve-
nous pressure‐RV dysfunction‐preoperative intubation‐se-
vere tricuspid regurgitation‐tachycardia (CRITT) (AUC 
0.74), right ventricle to left ventricle (RV/LV) ratio 
(AUC 0.71), RV stroke work index (RVSWI) (AUC 0.71), 
tricuspid annular plane systolic excursion (TAPSE) (AUC 
0.70), MELD (AUC 0.69), CVP/PCWP ratio (AUC 0.68), 
Severe TR (AUC 0.67), HMII RVF score (AUC 0.64), and 
Michigan score (AUC 0.61). On AUC comparison, the 
MCSRN RVF risk score performed better than other scores 
tested (Table 4 and Figure 3).
4 |  DISCUSSION
Out of the commonly used risk models for RVF in CF‐LVAD 
patients, none of them have been developed with a contem-
porary patient population. We were not able to identify an 
existing model with strong performance (AUC 0.80–0.89) to 
predict acute severe RVF requiring RVAD after CF‐LVAD 
implantation. In contrast, the AUC for our risk model reached 
0.89 for the entire sample and there was no drop in the 
AUC from derivation (AUC 0.86) to validation (AUC 0.92) 
T A B L E  3  Model derived from the derivation cohort after logarithmic data transformation and backward stepwise logistic regression
Variable OR Lower 95% CI Upper 95% CI P value
log(HR) 67.3 5.2 867.1 <0.01
log(Albumin) 0.01 0.0 0.4 0.01
log(BUN) 3.0 1.1 8.2 0.03
log(WBC) 4.2 1.0 17.9 0.05
log(CI) 0.1 0.0 0.4 <0.01
Numeric value of TR severity 2.4 1.5 3.8 <0.01
F I G U R E  1  Receiver operating characteristic analysis of the 
novel RV risk model [Color figure can be viewed at  
wileyonlinelibrary.com]
F I G U R E  2  Restricted cubic splines analysis showing continuous 
relationship between the risk model values and the odds ratios of 
requiring an RVAD. Odds ratio of needing an RVAD approaches 0 
with lower values of the risk model [Color figure can be viewed at 
wileyonlinelibrary.com]
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cohorts, indicating a strong performance. We chose to use 
a RVAD as the primary outcome due to varying definitions 
of RVF at our institutions, many of which are dependent on 
institutional practice variation in management of inotropes or 
nitric oxide after CF‐LVAD as opposed to an RVAD which 
is only employed in the sickest cohort of patients with acute 
severe RVF.
Variables identified to predict RV failure after LVAD 
placement vary widely1,9,10,14,15 and reflect the complexity 
in the multifactorial mechanism of the RV failure onset. 
While no single best predictor variable has been identified, 
some form of RV hemodynamics9,10,16 or tricuspid valve 
function6,8 surrogates are most commonly used alone6,8‒10,16 
or as part of a predictive risk score.1,4 Additional variables 
reflective of renal1,7 and liver7,17 function have commonly 
been factored in the prediction process, however are not 
used alone. Heart rate and cardiac index represent hemo-
dynamic variables that are not specific for the RV function 
and, to a degree, it is surprising to find them in the final 
model as they can be altered significantly with different 
interventions. However, other predictive risk models have 
used these variables as well.4,18 WBC count has also been 
identified among the variables associated with RV failure 
in CF‐LVAD patients1,4 and may be reflective of a systemic 
component of the disease, or a sicker patient. An import-
ant part of our risk model development process that (to the 
best of our knowledge) has not been employed in deriving 
other risk models is not dichotomizing continuous data. 
This, while imposing additional steps (like logarithmic 
data transformation) on the process, is more likely to retain 
the predictive strength both in individual variables and the 
combined model.
While dichotomization of the continuous variables 
should be avoided, cut‐off values for the continuous scale 
can be helpful in aiding the physician in the decision pro-
cess, hence the need for identifying an optimal cut‐off 
that minimizes the compromise between sensitivity and 
specificity. The cut‐off level of approximately 22 resulted 
in good sensitivity (88.4%) and fair specificity (78.3%). 
While the negative predictive value was poor (25.7%), 
the positive predictive value at this cut‐off was excellent 
(98.8%). Although the negative predictive value was low, 
the positive predictive value of the model makes it a very 
useful tool to identify high‐risk patients in the preoperative 
period who would benefit from a temporary or permanent 
RVAD to mitigate perioperative morbidity and mortality. 
T A B L E  4  Receiver operating characteristic analysis of commonly used RVF predictors applied to the full MCSRN data set (n = 734) with 
need for RVAD as a hard endpoint.
Predictor AUC 98% CI
P value compared with  
MCSRN RVF Risk Score
MCSRN RVF 0.89 0.82–0.96 –
PAPI 0.78 0.66–0.89 <0.01
CRITT 0.74 0.60–0.89 0.02
RVSWI 0.71 0.59–0.83 <0.01
TAPSE 0.70 0.48–0.92 <0.01
MELD score 0.69 0.60–0.79 0.05
CVP/PCWP ratio 0.68 0.58–0.79 <0.01
Severe TR 0.67 0.59–0.76 <0.01
HMII RVF score 0.64 0.48–0.79 0.05
Michigan score 0.61 0.48–0.74 <0.01
CRITT, central venous pressure‐RV dysfunction‐preoperative intubation‐severe tricuspid regurgitation‐tachycardia; MELD, model for end‐stage liver disease; PAPI, 
pulmonary artery pulsatility index; RVSWI, RV stroke work index; TAPSE, tricuspid annular plane systolic excursion.
F I G U R E  3  Receiver operating characteristic curves illustrating 
the performance of commonly used RVF predictors. AUC: area under 
the curve [Color figure can be viewed at wileyonlinelibrary.com]
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As well, it may be helpful to identify “less ideal” candi-
dates for LVAD, especially those who are being considered 
DT‐LVAD. The numeric value of the model can be of ad-
ditional use as the further it deviates from the cut‐off, the 
more likely that the outcome becomes positive or negative, 
further aiding the clinician in decision making.
In medicine, despite many prognostic models that are pub-
lished each year, relatively few are validated and even fewer 
find their way into clinical practice.19 This is true for RVF 
risk models as well. Deriving and validating a model on the 
same data set leads to overly optimistic estimates of the mod-
el’s accuracy, even if the data set is divided into 2 separate 
parts for model derivation and validation.19 This is because 
“quirks” individual to a data set will also occur in both the 
derivation and validation samples that are derived from the 
same data set and may lead to optimistic estimates of prog-
nostic power.20 Therefore, the existing risk scores performed 
worse using an independent sample set when compared to 
the data set used for its development. This effect, however, is 
even more prominent with smaller, single‐institution samples 
that will allow higher variation. Our risk model still needs 
validation in an external data set.
4.1 | Study limitations
Even though the analysis was performed using a multi‐insti-
tutional registry, both patient samples (derivation and valida-
tion) stem from the same data and therefore display similar 
comorbidities and intervention patterns. In addition, there 
may be similar unidentified confounders in both samples that 
were not picked up by the analysis and may pose a risk of 
systemic bias. Because of these reasons, this “split‐sample 
validation” can be overly optimistic and our results should be 
interpreted with caution.
Our model has 6 variables. A generally recommended 
number of predictor variables in a model is one variable 
per 10–20 events. As we only had 15 outcome events, we 
were not able to follow this recommendation. Otherwise, 
the low number of RVAD events would not leave us with 
any model at all. In contrast, the more candidate variables 
there are in the model, the more opportunity there is for 
some of those variables to end up in the model purely by 
chance. This is possible for our model as well; however, 
we used AIC to mitigate the problem (as AIC rewards for 
significance while punishing for higher number of predic-
tor variables).
We chose RVAD implant as the endpoint for the risk 
model as it was a hard endpoint, not influenced by local or in-
stitutional practices. One obvious downside is that RVAD is 
a rare event. With just RVAD as an endpoint, the model may 
not fully encompass risk stratification of a much larger group 
of patients with RV failure without the need for RVAD and, 
as such, may lack in generalizability. In contrast, the strength 
of the model is that it produces a numeric score where higher 
values should intuitively mean higher risk for RV failure, 
even without an RVAD.
In summary, the present model should be considered as 
an exploratory tool rather than a validated risk score due to 
low rate of events in both groups. To control for these po-
tential confounders and demonstrate such a generalizabil-
ity, a rigorous external validation process by other authors 
is required.
5 |  CONCLUSIONS
To conclude, the proposed RVF MCSRN risk score pro-
vides the highest‐to‐date discriminatory power with an 
AUC of 0.89 which favors comparably to already pub-
lished models. The risk score is applicable to contempo-
rary patients implanted with CF‐LVADs. After appropriate 
validation, the risk score may be used to identify patients 
at very high risk for severe right ventricular failure after 
LVAD who would benefit from either a temporary or per-
manent RVAD.
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